Lonza Ag

Lonza Inc.

Sankyo Company, Limited

Josef Heveling

Alain Wellig

Erich Armbruster

Yves Bessard

Andreas Gerhard

Ulrich Daum

Olaf Frei

Roderick J Chuck

Walter Siegrist

David Laffan

Alkis Sofianos

Lukas Utiger

Hans-Rudolf Dettwiler

Markus Rohner

A new process for the catalytic conversion of hydroxymethyl imidazoles to formylimidazoles is described. The reaction takes place in the presence of a peroxide. Formylimidazoles are important intermediate products for pharmaceutical substances.

Procedure for producing formylimidazoles

A new procedure for the catalytic conversion of hydroxy methyl imidazoles to formyl imidazoles is described. The catalysis takes place in the presence of a peroxide. Formyl imidazoles are important intermediate products for pharmaceutical substances.

Procedure for producing formyl imidazoles

Piperidinopentanamines, process for producing them and their use as a

Catalyst compositions based on amorphous partially dehydrated zirconium hydroxide which are doped with from 0.01 to 20 atom percent of copper and/or from 0.01 to 20 atom percent of nickel, in each case based on zirconium, and have a specific surface area by the BET method of at least 50 m.sup.2 /g. The catalyst compositions are suitable, in particular, as the catalyst in hydrogen transfer reactions, such as, the Meerwein-Ponndorf-Verley reduction or the Oppenauer oxidation. The preparation of 3-hydroxyquinuclidine of the formula: ##STR1## involves reaction of quinuclidin-3-one with a secondary alcohol in the presence of the amorphous partially dehydrated zirconium hydroxide.

Catalysts containing zirconium oxide

Process for producing methanol and catalyst therefor

A process for the catalytic conversion of hydroxymethylimidazoles to formylimidazoles. The catalysis takes place in the presence of a peroxide. Formylimidazoles are important intermediates for pharmaceutical active ingredients.

Process for the preparation of formylimidazoles

A process for the catalytic conversion of halogenated hydroxymethylimidazoles to halogenated formylimidazoles. The catalysis takes place in the presence of a peroxide. Halogenated formylimidazoles are important intermediates for pharmaceutical active ingredients.

A process for preparing nicotinamide, wherein, in the first stage, 2-methyl-1,5-diaminopentane is catalytically converted into 3-picoline, then the 3-picoline is converted via an ammonoxidation into 3-cyanopyridine and, finally, the 3-cyanopyridine is converted microbiologically into the nicotinamide.

Process for preparing nicotinamide

Process for the preparation of 3-methylpiperidine and 3-methylpyridine

Tertiary diamine, its use as catalyst, and process for preparing

A novel process for the preparation of aminochromans of the general formula: ##STR1## wherein R is a C.sub.1 -C.sub.4 alkyl group. In the process, a nitrochromanone of the general formula: ##STR2## is hydrogenated with hydrogen in the presence of a hydrogenation catalyst. The resultant aminochromanone (III) is reduced using zirconium oxide/isopropanol to the aminochromene (IV). The latter is finally hydrogenated with hydrogen in the presence of a hydrogenation catalyst to give the final product. The aminochromans are useful intermediates for the preparation of hypolipidaemic pharmaceuticals.

Method for the preparation of

A novel process for the preparation of aminochromans of the general formula: ##STR1## wherein R is a lower alkyl group having 1 to 4 carbon atoms. In the process, nitrochromanones of the general formula: ##STR2## are reduced using zirconium oxide/isopropanol to give a mixture of a corresponding aminochromene: ##STR3## and a corresponding nitrochromene: ##STR4## The mixture is then hydrogenated with hydrogen in the presence of a hydrogenation catalyst to give the final product. The aminochromans are important intermediates for the preparation of hypolipidaemic pharmaceuticals.

Growing community of inventors

Naters, Switzerland

Josef Heveling